Stockscreener 앱 받기
4.25
1.67%
0.07
시간 외 거래:
4.07
-0.18
-4.24%
전일 마감가:
$4.18
열려 있는:
$3.82
하루 거래량:
95,357
Relative Volume:
0.03
시가총액:
$8.12M
수익:
-
순이익/손실:
$-5.73M
주가수익비율:
-0.6489
EPS:
-6.55
순현금흐름:
$-4.13M
1주 성능:
-24.65%
1개월 성능:
+2.41%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$3.82
$4.34
1주일 범위
$3.715
$5.53
52주 변동 폭
$1.62
$29.28
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
명칭
Dogwood Therapeutics Inc
전화
(866) 620-8655
주소
44 MILTON AVENUE, ALPHARETTA
DWTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
4.25 | 8.12M | 0 | -5.73M | -4.13M | -6.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Dogwood Therapeutics Inc 주식(DWTX)의 최신 뉴스
DWTX: Interim Data for Phase 2b Trial in 4Q25… - Yahoo Finance
Dogwood Therapeutics Announces Nasdaq Compliance Regained - Nasdaq
Dogwood Therapeutics regains Nasdaq compliance - Investing.com
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance - GlobeNewswire
Dogwood Therapeutics Saves Nasdaq Status: $17.5M Cash, Zero Debt After Major Financial Overhaul - Stock Titan
Dogwood Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Dogwood Therapeutics, Inc. SEC 10-K Report - TradingView
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Dogwood Strengthens Balance Sheet with $24M Capital Actions as Halneuron Trial Progresses - Stock Titan
Dogwood Therapeutics begins Phase 2b trial for neuropathic pain By Investing.com - Investing.com South Africa
DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet… - Zacks Small Cap Research
Dogwood Therapeutics Begins Dosing in Mid-Stage Study of Halneuron for Chemotherapy-Related Neuropathic Pain - Marketscreener.com
Dogwood Therapeutics begins Phase 2b trial for neuropathic pain - Investing.com
Dogwood Therapeutics Announces Dosing of First Patient in - GlobeNewswire
Revolutionary Non-Addictive Pain Treatment Enters Critical Phase 2b Trial for Cancer Patients - StockTitan
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Dogwood Therapeutics announces pricing of $4.8 million offering - MSN
Dogwood Therapeutics Launches Registered Direct Offering; Shares Plunge -March 13, 2025 at 09:40 am EDT - Marketscreener.com
Dogwood Therapeutics secures $4.8 million in direct offering By Investing.com - Investing.com Australia
Dogwood Therapeutics secures $4.8 million in direct offering - Investing.com
Dogwood Therapeutics Secures $4.8 Million in Direct Offering to Advance Halneuron® Phase 2b Trial and Fund Operations Through Q1 2026 - Nasdaq
Dogwood Therapeutics, Inc. Announces Pricing of $4.8 - GlobeNewswire
Dogwood Secures Critical Funding for Revolutionary Pain Treatment: What's Next for Halneuron? - StockTitan
Dogwood Therapeutics clears debt with equity swa By Investing.com - Investing.com Australia
Dogwood Therapeutics converts existing debt to equity -March 12, 2025 at 10:34 am EDT - Marketscreener.com
Dogwood Therapeutics Strengthens Balance Sheet with Debt Conversion - TipRanks
Dogwood Therapeutics clears debt with equity swa - Investing.com
Dogwood Therapeutics Announces Debt-to-Equity Exchange with CK Life Sciences, Strengthening Financial Position for Clinical Trials - Nasdaq
Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward - Financial Post
Dogwood Therapeutics, Inc. Announces Conversion of Existing - GlobeNewswire
Major Breakthrough: Dogwood Therapeutics Wipes Out All Debt as Top Investor Backs Pain Drug Future - StockTitan
Dogwood Therapeutics (DWTX) to Release Earnings on Thursday - Defense World
Dogwood Therapeutics Inc expected to post a loss of $1.41 a shareEarnings Preview - TradingView
DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth - MSN
Closing Figures Unveiled: Dogwood Therapeutics Inc (DWTX) Gain 13.53, Closes at 14.18 - The Dwinnex
Dogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370% Surge - MSN
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Stock market news: Planet Image International +132.83%, Akero Therapeutics +94.04% among top gainers during mid day trading - Business Upturn
Stock market news: Planet Image International surged by 160.47% while Allakos is still declining by 80.30% during mid day trading - Business Upturn
Dogwood Therapeutics : Corporate Presentation (DWTX Inc. Corporate Overview Q1 2025) - Marketscreener.com
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Dogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370% Su - Asianet Newsable
Clinical trial published in Nature Medicine shows proof of concept of PAGE's Therapeutics approach - Yahoo Finance
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders - Yahoo Finance
Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Yahoo Finance
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia - Yahoo Finance
Is This Breakthrough the Future of Pain Management? A New Hope is Here! - Slapenas
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics - Yahoo Finance
Dogwood Therapeutics Inc (DWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):